Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

11/12/24 10:34:15 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TYRA alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 TYRA BIOSCIENCES INC COMMON STOCK Cusip #90240B106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #90240B106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,372,435 Item 6: 0 Item 7: 3,372,850 Item 8: 0 Item 9: 3,372,850 Item 11: 6.387% Item 12: HC Cusip #90240B106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,372,850 Item 8: 0 Item 9: 3,372,850 Item 11: 6.387% Item 12: IN Item 1(a). Name of Issuer: TYRA BIOSCIENCES INC Item 1(b). Address of Issuer's Principal Executive Offices: 2656 STATE STREET CARLSBAD, CA 92008 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 90240B106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 3,372,850 (b) Percent of Class: 6.387% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 3,372,850 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TYRA BIOSCIENCES INC. No one other person's interest in the COMMON STOCK of TYRA BIOSCIENCES INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of TYRA BIOSCIENCES INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $TYRA alert in real time by email

Recent Analyst Ratings for

$TYRA

Date	Price Target	Rating	Analyst
5/21/2025	$33.00	Overweight	Piper Sandler
1/7/2025	$28.00	Buy	UBS
10/18/2024	$22.00 → $31.00	Neutral → Buy	BofA Securities
8/15/2024	$33.00	Overweight	Piper Sandler
12/15/2023	$25.00 → $15.00	Buy → Neutral	BofA Securities
6/30/2023	$27.00	Outperform	Wedbush
2/3/2023	$17.00	Outperform	Oppenheimer
6/23/2022	$12.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

11/12/24 10:34:15 AM ET

$TYRA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TYRA alert in real time by email

Recent Analyst Ratings for

$TYRA

Date	Price Target	Rating	Analyst
5/21/2025	$33.00	Overweight	Piper Sandler
1/7/2025	$28.00	Buy	UBS
10/18/2024	$22.00 → $31.00	Neutral → Buy	BofA Securities
8/15/2024	$33.00	Overweight	Piper Sandler
12/15/2023	$25.00 → $15.00	Buy → Neutral	BofA Securities
6/30/2023	$27.00	Outperform	Wedbush
2/3/2023	$17.00	Outperform	Oppenheimer
6/23/2022	$12.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $TYRA

Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $TYRA

$TYRA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Kaplan Gilla sold $93,700 worth of shares (9,578 units at $9.78), decreasing direct ownership by 25% to 28,231 units (SEC Form 4)

Director Ra Capital Management, L.P. bought $1,664,700 worth of shares (163,287 units at $10.19) (SEC Form 4)

Director Kaplan Gilla sold $534,563 worth of shares (51,814 units at $10.32), decreasing direct ownership by 58% to 37,809 units (SEC Form 4)

$TYRA Press Releases

Fastest customizable press release news feed in the world

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences to Participate at Upcoming Investor Conferences

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

$TYRA SEC Filings

SEC Form 8-K filed by Tyra Biosciences Inc.

SEC Form 144 filed by Tyra Biosciences Inc.

SEC Form 144 filed by Tyra Biosciences Inc.

$TYRA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler resumed coverage on Tyra Biosciences with a new price target

UBS initiated coverage on Tyra Biosciences with a new price target

Tyra Biosciences upgraded by BofA Securities with a new price target

$TYRA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. bought $1,664,700 worth of shares (163,287 units at $10.19) (SEC Form 4)

Director Ra Capital Management, L.P. bought $1,904,002 worth of shares (186,850 units at $10.19) (SEC Form 4)

Director Ra Capital Management, L.P. bought $11,751,304 worth of shares (1,211,198 units at $9.70) (SEC Form 4)

$TYRA Leadership Updates

Live Leadership Updates

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

$TYRA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

$TYRA Financials

Live finance-specific insights

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

Recent Analyst Ratings for
$TYRA

Recent Analyst Ratings for
$TYRA

$TYRA
Insider Trading

$TYRA
Press Releases

$TYRA
SEC Filings

$TYRA
Analyst Ratings

$TYRA
Insider Purchases

$TYRA
Leadership Updates

$TYRA
Large Ownership Changes

$TYRA
Financials